DJIA 18,135.72 38.82 0.21%
NASDAQ 4,982.81 15.67 0.32%
S&P 500 2,101.04 2.51 0.12%
market minute promo

Express Scripts (NASDAQ: ESRX)



company name or ticker
Company Photos
(Click to zoom)

How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

AbbVie Inc. has issued earnings guidance for 2015 that calls for 30% growth.

Steven Romick Buys 7 US and International Stocks in Q4

AbbVie Inc.'s Forthcoming Future Looks Optimistic

Will Earnings or the European Central Bank Prompt U.S. Stocks to Rise?

Amgen's Decline May Be Linked To Comments Of Express Script's CEO

Express Scripts CEO: Amgen, Regeneron, Cancer Drugs Next Targets for Drug Discounting

3 Stocks Dragging In The Health Services Industry

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

1 Big Loser in the Slugfest Between AbbVie and Gilead Sciences

It's a heavyweight hep-C bout between AbbVie and Gilead Sciences. Who is losing?

Which Big Biotech Will Soar in 2015?

Motley Fool contributors think that Gilead Sciences, Biogen Idec, and Celgene Corp could be top performers in 2015.